TY - JOUR
T1 - Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anaemia
AU - Alkindi, S.
AU - Elsadek, R. A.
AU - Al-Madhani, A.
AU - Al-Musalhi, M.
AU - AlKindi, S. Y.
AU - Al-Khadouri, G.
AU - Al Rawahi, Bader
AU - Al-Ruqeishi, S.
AU - Al-Yazeedi, J.
AU - Wali, Y. A.
AU - Al Shamakhi, S.
AU - Al Rawahi, M.
AU - Pathare, A. V.
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/5
Y1 - 2021/5
N2 - Objectives: The study aimed to assess COVID-19 impact on the morbidity and mortality of vasooclusive crisis (VOC) in sickle cell anaemia (SCA) patients. Methods: A prospective cohort study of 100 SCA patients; 50 with COVID-19 (COVID group) and 50 without (non-COVID group). All patients signed written informed consent. Results: The COVID group had a significantly higher VOC episode median per year; 3 (IQR,1-6) vs 2 (IQR,2-12) (P < 0.05). The need for hospitalisation was similar in both groups. The non-COVID group had more history of culture-proven infection (P = 0.05). The COVID-group had more osteonecrosis (P < 0.05), splenic sequestration, splenomegaly and hepatic crisis (P = 0.05, 0.006, 0.02; respectively) and significantly higher (P < 0.05) symptoms of fever, cough, fatigue, abdominal pain and anosmia. Mean haemoglobin, lymphocyte subset, platelets, and reticulocytes were reduced in both groups, while lactate dehydrogenase and ferritin levels were significantly elevated. In the COVID group, the rise in white blood cell count, reticulocyte percentage, platelets and ferritin was subdued (P < 0.05). Two patients in the COVID group and 3 in the non-COVID group died; there was no statistically significant difference in mortality. Conclusions: Although COVID-19 may have triggered the onset of VOC, it did not significantly influence VOC-related morbidity or mortality in this SCA cohort.
AB - Objectives: The study aimed to assess COVID-19 impact on the morbidity and mortality of vasooclusive crisis (VOC) in sickle cell anaemia (SCA) patients. Methods: A prospective cohort study of 100 SCA patients; 50 with COVID-19 (COVID group) and 50 without (non-COVID group). All patients signed written informed consent. Results: The COVID group had a significantly higher VOC episode median per year; 3 (IQR,1-6) vs 2 (IQR,2-12) (P < 0.05). The need for hospitalisation was similar in both groups. The non-COVID group had more history of culture-proven infection (P = 0.05). The COVID-group had more osteonecrosis (P < 0.05), splenic sequestration, splenomegaly and hepatic crisis (P = 0.05, 0.006, 0.02; respectively) and significantly higher (P < 0.05) symptoms of fever, cough, fatigue, abdominal pain and anosmia. Mean haemoglobin, lymphocyte subset, platelets, and reticulocytes were reduced in both groups, while lactate dehydrogenase and ferritin levels were significantly elevated. In the COVID group, the rise in white blood cell count, reticulocyte percentage, platelets and ferritin was subdued (P < 0.05). Two patients in the COVID group and 3 in the non-COVID group died; there was no statistically significant difference in mortality. Conclusions: Although COVID-19 may have triggered the onset of VOC, it did not significantly influence VOC-related morbidity or mortality in this SCA cohort.
KW - COVID-19
KW - Coronavirus
KW - SCA
KW - Sickle cell anaemia
KW - Vasooclusive crises
UR - http://www.scopus.com/inward/record.url?scp=85104050046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104050046&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2021.03.044
DO - 10.1016/j.ijid.2021.03.044
M3 - Article
C2 - 33741487
AN - SCOPUS:85104050046
SN - 1201-9712
VL - 106
SP - 128
EP - 133
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -
